Home › Therapeutic areas › Oncology › Head and Neck Cancer
Head and Neck Cancer (10 companies)
Companies with an active program in Head and Neck Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.27B | 6 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.39B | 9 |
| BCAX | Bicara Therapeutics | Oncology | 1 | Phase 2 | $572M | 4 |
| CUE | Cue Biopharma | ImmunologyOncology | 1 | Phase 2 | $136M | 6 |
| IMTX | Immatics | Oncology | 1 | Phase 3 | $968M | 8 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.24B | 6 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $2.09B | 12 |
No companies match.